Medtronic announces fda approval of newest-generation evolut tavr system for treatment of symptomatic severe aortic stenosis

The evolut™ fx+ tavr system leverages market-leading valve performance with addition of larger windows to facilitate coronary access dublin , march 27, 2024 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced that the united states food and drug administration (fda) has approved the evolut™ fx+ transcatheter aortic valve replacement (tavr) system for the treatment of symptomatic severe aortic stenosis. the latest evolut fx+ tavr system maintains the valve performance benefits of the legacy evolut tavr platform and is designed to facilitate coronary access.
MDT Ratings Summary
MDT Quant Ranking